PO.CL01.20 · 临床研究

针对严重降解FFPE样本的稳健RNA-seq解决方案:PredicineWTS Tissue NGS平台

A robust RNA-seq solution for severely degraded FFPE samples: The PredicineWTS Tissue NGS platform

海报缩略图:针对严重降解FFPE样本的稳健RNA-seq解决方案:PredicineWTS Tissue NGS平台
编号 3818 展板 2 时间 4/20 02:00–05:00 区域 Section 44 主讲 Min Wang
分会场 Diagnostic Biomarkers 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Min Wang, Yasser Abdelrahman, Guanglong Jiang, Yong Huang, Pan Du, Binggang Xiang

Predicine, Inc., Hayward, CA

摘要 Abstract

中文摘要
背景:福尔马林固定石蜡包埋(FFPE)组织仍是癌症研究和发现临床相关生物标志物的重要资源。然而,从FFPE样本提取的RNA往往高度降解、经化学修饰且断裂,给转录组分析(包括基因表达谱分析和RNA融合检测)带来重大挑战。为满足对能够处理严重降解RNA的稳健RNA-seq方法的需求,我们开发了PredicineWTS Tissue平台,该平台将优化的提取化学技术与专为FFPE RNA定制的专有RNA-seq流程相整合。 方法:PredicineWTS Tissue平台采用专有提取方案,从单张FFPE切片同时分离DNA和RNA,最大化材料在多组学应用中的利用率。RNA-seq工作流程支持低至10 ng的输入量,并耐受极端降解,包括DV200值低至10%。定制的生物信息学流程可实现全面的表达谱分析以及RNA融合和剪接变异的检测。提取过程中分离的DNA被保存用于下游基因组检测,从而实现整合分析。使用商业参考物质进行了性能验证。 结果:该平台在严重降解的FFPE RNA上表现优异。从DV200值低至10%的样本中生成了高质量文库,实现约93%的唯一比对读段、90%的外显子读段以及约19,000个基因的检测。表达准确性与一家独立第三方公司的结果高度相关(Pearson r ≥ 0.94)。使用梯度稀释的Seraseq材料(50%、20%、10%和5%肿瘤纯度)评估了融合检测灵敏度,所有预期融合在低至10%肿瘤纯度时均被检测到,支持了对癌症生物标志物发现相关的低丰度事件的灵敏度。提取过程中回收的DNA显示出与领先提取方法相当的产量和质量,进一步支持了工作流程的多功能性。 结论:PredicineWTS Tissue检测为严重降解的FFPE样本提供了强大而可靠的RNA-seq解决方案。通过在低RNA质量和低输入量下实现稳健的表达谱分析和灵敏的融合检测,该平台推进了生物标志物发现并支持整合多组学研究。其在存档和具有挑战性的FFPE材料上的表现使其成为精准肿瘤学和转化研究的宝贵技术。
查看英文原文 English abstract
Background: Formalin-fixed, paraffin-embedded (FFPE) tissues remain essential resources for cancer research and the discovery of clinically relevant biomarkers. However, RNA extracted from FFPE samples is often highly degraded, chemically modified, and fragmented, posing major challenges for transcriptomic analyses, including gene expression profiling and RNA fusion detection. To address the need for a robust RNA-seq method capable of handling severely degraded RNA, we developed the PredicineWTS Tissue platform, which integrates optimized extraction chemistry with a proprietary RNA-seq pipeline tailored for FFPE RNA. Methods: The PredicineWTS Tissue platform employs a proprietary extraction protocol that simultaneously isolates DNA and RNA from a single FFPE section, maximizing material utility for multi-omics applications. The RNA-seq workflow supports inputs as low as 10 ng and tolerates extreme degradation, including DV200 values down to 10%. A customized bioinformatics pipeline enables comprehensive expression profiling and detection of RNA fusions and splicing variants. DNA isolated during extraction is preserved for downstream genomic assays, enabling integrated analyses. Performance validation was performed using commercial reference materials. Results: The platform showed strong performance on heavily degraded FFPE RNA. High-quality libraries were generated from samples with DV200 values as low as 10%, achieving approximately 93% uniquely mapped reads, 90% exonic reads, and detection of ~19,000 genes. Expression accuracy correlated strongly with an independent third-party company's results (Pearson r ≥ 0.94). Fusion detection sensitivity was evaluated using titrated Seraseq material (50%, 20%, 10%, and 5% tumor purity), and all expected fusions were detected down to the 10% tumor purity, supporting sensitivity for low-abundance events relevant to cancer biomarker discovery. DNA recovered during extraction showed yield and quality comparable to leading extraction methods, further supporting workflow versatility. Conclusion: PredicineWTS Tissue assay provides a powerful and reliable RNA-seq solution of severely degraded FFPE samples. By enabling robust expression profiling and sensitive fusion detection at low RNA quality and input, the platform advances biomarker discovery and supports integrated multi-omics studies. Its performance with archival and challenging FFPE material positions it as a valuable technology for precision oncology and translational research.
利益披露 Disclosure
M. Wang, Predicine, Inc. Employment. Y. Abdelrahman, Predicine, Inc. Employment. G. Jiang, Predicine, Inc. Employment. Y. Huang, Predicine, Inc. Employment. P. Du, Predicine, Inc. Employment. B. Xiang, Predicine, Inc. Employment.

← 返回 AACR 2026 检索